Evaluation of Anticancer Activity of Zhubech, a New 5-FU Analog Liposomal Formulation, against Pancreatic Cancer

Pancreatic cancer is projected to be the second leading cause of cancer-related death by 2030 in the US. The benefits of the most common systemic therapy for various pancreatic cancers have been masked by high drug toxicities, adverse reactions, and resistance. The use of nanocarriers such as liposo...

Descripción completa

Detalles Bibliográficos
Autores principales: Ndemazie, Nkafu Bechem, Bulusu, Raviteja, Zhu, Xue You, Frimpong, Esther Kesewaah, Inkoom, Andriana, Okoro, Joy, Ebesoh, Dexter, Rogers, Sherise, Han, Bo, Agyare, Edward
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10002367/
https://www.ncbi.nlm.nih.gov/pubmed/36901721
http://dx.doi.org/10.3390/ijms24054288

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10002367/
https://www.ncbi.nlm.nih.gov/pubmed/36901721
http://dx.doi.org/10.3390/ijms24054288

Ejemplares similares